Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.50 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.47 |
| ▸ | SELE | P16581 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | TSPO | P30536 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL944347 | 0.87 | CTNNB1 (0.65) | CTNNB1MAPK1ALDH1A1HSD17B10KDM4C | |
| SCHEMBL2657045 | 0.87 | KDM4C (0.56) | CTNNB1MAPK1ALDH1A1HSD17B10KDM4C | |
| SCHEMBL1326854 | 0.84 | SIRT3 (0.54) | CTNNB1ALDH1A1GPBAR1SIRT3TDP1 | |
| SCHEMBL3886702 | 0.82 | MAPT (0.50) | CTNNB1ALDH1A1GPBAR1SIRT3TDP1 | |
| Hydrochloric Acid SCHEMBL6831891 | 0.82 | ALDH1A1 (0.48) | CTNNB1ALDH1A1GPBAR1SIRT3TDP1 | |
| SCHEMBL4042446 | 0.81 | TDP1 (0.55) | CTNNB1MAPK1ALDH1A1HSD17B10KDM4C | |
| SCHEMBL27569244 | 0.81 | HTT (0.55) | CTNNB1ALDH1A1GPBAR1SIRT3TDP1 | |
| SCHEMBL17397069 | 0.80 | CTNNB1 (0.74) | CTNNB1MAPK1ALDH1A1HSD17B10KDM4C | |
| SCHEMBL10969028 | 0.80 | ICAM1 (0.56) | ALDH1A1ICAM1SELESMN1; SMN2KDM4E | |
| SCHEMBL5755203 | 0.80 | SIRT3 (0.42) | CTNNB1MAPK1GPBAR1SIRT3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154634-B1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | UNIV LILLE (FR) | 2021-02-24 | — | — | EP | disclosed |
| US-10323016-B2 | Imidazol- or 1,2,4-triazol-derivatives and their use | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2019-06-18 | — | — | US | disclosed |
| US-9932309-B2 | 2-oxo-3,4-dihydropyridine-5-carboxylates and their use | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2018-04-03 | — | — | US | disclosed |
| WO-2017134188-A1 | NOVEL DIHYDROPYRIDINONE AND DIHYDROPYRIMIDINONE COMPOUNDS AND THEIR USE | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2017-08-10 | — | — | WO | disclosed |
| US-20170210710-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-07-27 | — | — | US | disclosed |
| US-20170190687-A1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | Université de Lille (FR) | 2017-07-06 | — | — | US | disclosed |
| EP-3174872-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | Université de Lille 2 Droit et Santé (FR) | 2017-06-07 | — | — | EP | disclosed |
| EP-3154634-A1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | Université de Lille 2 Droit et Santé (FR) | 2017-04-19 | — | — | EP | disclosed |
| WO-2017042380-A1 | NOVEL 5-AMINO-2-THIOIMIDAZOLE COMPOUNDS AND THEIR USE | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2017-03-16 | — | — | WO | disclosed |
| WO-2016149628-A1 | TGR5 AGONISTS | CHEMBRIDGE CORPORATION (US) | 2016-09-22 | — | — | WO | disclosed |
| EP-1747276-A2 | CAROTENOID BIOSYNTHESIS INHIBITOR RESISTANCE GENES AND METHODS OF USE IN PLANTS | BASF Plant Science GmbH (DE) | 2007-01-31 | — | — | EP | disclosed |
| EP-1651609-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005111218-A2 | CAROTENOID BIOSYNTHESIS INHIBITOR RESISTANCE GENES AND METHODS OF USE IN PLANTS | BASF PLANT SCIENCE GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| CN-1681498-A | Diaryl ethers as opioid receptor antagonist | LILLY CO ELI (US) | 2005-10-12 | — | — | CN | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| WO-2005009966-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| US-6407111-B1 | SUBSTANCE P OR NEUROKININ 1 ANTAGONISTS; ANTIINFLAMMATORY, ANTIDEPRESSANT, ANTIARTHRITIC, AND ANTIASTHMATIC AGENTS; PARKINSON*S DISEASE, INFLAMMATORY BOWEL DISEASE, CENTRAL NERVOUS SYSTEM AND RHEUMATIC DISORDERS | HOFFMANN-LA ROCHE INC. | 2002-06-18 | — | — | US | disclosed |
| US-5422247-A | A grampositive or mutants of BLAKESLEA TRISPORA forming a mated culture product with gramnegative BLAKESLEA TRISPORA | UNIVERSAL FOODS CORPORATION (US) | 1995-06-06 | — | — | US | disclosed |
| US-5328845-A | Fungal negative microorganism capable of producing high levels of beta-carotene | UNIVERSAL FOODS CORPORATION (US) | 1994-07-12 | — | — | US | disclosed |
| WO-1993020183-A1 | METHOD FOR PRODUCING BETA-CAROTENE USING A FUNGAL MATED CULTURE | UNIVERSAL FOODS CORPORATION (US) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190687-A1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | CYP3A43, CYP51A1, CYP3A7 | CTNNB1 2473/4885MAPK1 947/4885ALDH1A1 436/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | CTNNB1 4405/4885MAPK1 2507/4885ALDH1A1 2036/4885 |
| US-20170210710-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | CYP3A5, CYP2D6, QDPR | CTNNB1 2018/4885MAPK1 4600/4885ALDH1A1 47/4885 |
| US-10323016-B2 | Imidazol- or 1,2,4-triazol-derivatives and their use | CYP3A43, CYP51A1, CYP3A7 | CTNNB1 2473/4885MAPK1 947/4885ALDH1A1 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.